Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2019

Home/Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2019

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2019

Drug Pipeline, Pharma & Healthcare

Publication ID:

GMD0319077

Publication Date:

March 29, 2019

Pages:

Publisher:

Global Markets Direct

Region:

Global

$3,500.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2019

Summary

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS). The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 2, 2 and 3 respectively.

Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Central Nervous System, Gastrointestinal, Immunology, Infectious Disease, Ophthalmology, Respiratory and Undisclosed which include indications Atopic Dermatitis (Atopic Eczema), Non-Alcoholic Steatohepatitis (NASH), Actinic (Solar) Keratosis, Acute Lung Injury, Alzheimer's Disease, Breast Cancer, Gastrointestinal Tract Cancer, Genital Warts (Condylomata Acuminata), High-Grade Glioma, Inflammation, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Melanoma, Metastatic Melanoma, Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Endocrine Tumor, Posterior Uveitis, Psoriasis, Retinitis Pigmentosa (Retinitis), Rheumatoid Arthritis, Soft Tissue Sarcoma, Solid Tumor, Thyroid Cancer, Unspecified and Warts.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development
Baliopharm AG
CytImmune Sciences Inc
Eyevensys SAS
G&E Corp
GlaxoSmithKline Plc
Inflamalps SA
Inmune Bio Inc
Philogen SpA
Promethera Biosciences SA
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Drug Profiles
Atrosab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosab (improved formulation) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYT-21625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize TNFRSF1A for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fibromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Product Development Milestones
Featured News & Press Releases
Mar 19, 2019: INmune Bio co-founder and CEO presented at Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Summit Europe 2019
Feb 11, 2019: INmune Bio awarded a $1 million grant for the development of XPro1595 for the treatment of Alzheimers Disease
Dec 11, 2018: Study results presented at San Antonio Breast Cancer Symposium 2018
Nov 15, 2018: Data from University of Pittsburgh on INB03 for Treatment of Melanoma Presented at the 33rd Annual Society for Immunotherapy of Cancer (SITC) Meeting
Aug 09, 2018: Eyevensys appoints new Board member, Gerald Cagle
Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
May 23, 2018: INmune Bio Initiates Phase I Clinical Trial of INB03
Mar 12, 2018: Nanotechnology Delivers a Two-Punch Combination With Big Potential for Patients With Rare Cancers
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
May 09, 2017: Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases
Apr 20, 2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development
Apr 11, 2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development
Oct 28, 2016: Philogen Receives Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma
May 31, 2016: Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors
Feb 18, 2016: Eyevensys Receives Orphan Drug Designation in the European Union for EYS606 for the Non-Infectious Uveitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Baliopharm AG, H1 2019
Pipeline by CytImmune Sciences Inc, H1 2019
Pipeline by Eyevensys SAS, H1 2019
Pipeline by G&E Corp, H1 2019
Pipeline by GlaxoSmithKline Plc, H1 2019
Pipeline by Inflamalps SA, H1 2019
Pipeline by Inmune Bio Inc, H1 2019
Pipeline by Philogen SpA, H1 2019
Pipeline by Promethera Biosciences SA, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019

List of Figures
List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Covered

Baliopharm AG
CytImmune Sciences Inc
Eyevensys SAS
G&E Corp
GlaxoSmithKline Plc
Inflamalps SA
Inmune Bio Inc
Philogen SpA
Promethera Biosciences SA

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".